All news

Myriad Genetics faces widening securities probes after 47% plunge

Alpha Vantage · scanx.trade · · AI-summarised by FinFlash

Multiple law firms have expanded investigations into Myriad Genetics for potential securities fraud after the stock fell 47% and the company slashed full-year 2026 revenue guidance by $90 million. Q2 revenue dropped 11% year-over-year, missing consensus, on reimbursement pressure, collection issues and lower average revenue per test.

Read original source

MYGN company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.